Should There be Concern About Autoimmune Diabetes in Adults? Current Evidence and Controversies

Current Diabetes Reports

Volumn 16, Issue 9, 2016, Pages

  Østergaard, Jakob Appel ^a   Laugesen, Esben ^a   Leslie, R David ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Adult; Autoimmune diseases; Autoimmunity; Diabetes mellitus; Diagnosis

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; HLA DRB1 ANTIGEN; INCRETIN; INSULIN; METFORMIN;

ADULT; AUTOIMMUNE DISEASE; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE CLASSIFICATION; ENVIRONMENTAL FACTOR; EVIDENCE BASED MEDICINE; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GENETICS; IMMUNE SYSTEM; IMMUNOLOGY; LATENT AUTOIMMUNE DIABETES IN ADULTS; METABOLISM; PATHOLOGY;

ADULT; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; IMMUNE SYSTEM; LATENT AUTOIMMUNE DIABETES IN ADULTS; PHENOTYPE;

EID: 84979771574     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-016-0780-0     Document Type: Review

References (76)

1. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky’s postulates revisited). Immunol Today. 1993;14(9):426–30. doi:10.1016/0167-5699(93)90244-F.
2. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature. 1990;347(6289):151–6. doi:10.1038/347151a0.
3. Lampeter EF, Homberg M, Quabeck K, Schaefer UW, Wernet P, Bertrams J, et al. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet. 1993;341(8855):1243–4.
4. Skyler JS. Prevention and reversal of type 1 diabetes—past challenges and future opportunities. Diabetes Care. 2015;38(6):997–1007. doi:10.2337/dc15-0349.
5. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383(9911):69–82. doi:10.1016/S0140-6736(13)60591-7.
6. Fortune MD, Guo H, Burren O, Schofield E, Walker NM, Ban M, et al. Statistical colocalization of genetic risk variants for related autoimmune diseases in the context of common controls. Nat Genet. 2015;47(7):839–46. doi:10.1038/ng.3330.
7. Li YR, Li J, Zhao SD, Bradfield JP, Mentch FD, Maggadottir SM, et al. Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases. Nat Med. 2015;21(9):1018–27. doi:10.1038/nm.3933.
8. Rakyan VK, Beyan H, Down TA, Hawa MI, Maslau S, Aden D, et al. Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis. PLoS Genet. 2011;7(9):e1002300. doi:10.1371/journal.pgen.1002300.
9. Hawa MI, Fava D, Medici F, Deng YJ, Notkins AL, De Mattia G, et al. Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diabetes Care. 2000;23(2):228–33.
10. Csorba TR, Lyon AW, Hollenberg MD. Autoimmunity and the pathogenesis of type 1 diabetes. Crit Rev Clin Lab Sci. 2010;47(2):51–71. doi:10.3109/10408361003787171.
11. Beyan H, Drexhage RC, van der Heul NL, de Wit H, Padmos RC, Schloot NC, et al. Monocyte gene-expression profiles associated with childhood-onset type 1 diabetes and disease risk: a study of identical twins. Diabetes. 2010;59(7):1751–5. doi:10.2337/db09-1433.
12. Pham MN, Hawa MI, Pfleger C, Roden M, Schernthaner G, Pozzilli P, et al. Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: action LADA 4. Diabetologia. 2011;54(7):1630–8. doi:10.1007/s00125-011-2088-6.
13. Padmos RC, Schloot NC, Beyan H, Ruwhof C, Staal FJ, de Ridder D, et al. Distinct monocyte gene-expression profiles in autoimmune diabetes. Diabetes. 2008;57(10):2768–73. doi:10.2337/db08-0496.
14. Beyan H, Goodier MR, Nawroly NS, Hawa MI, Bustin SA, Ogunkolade WB, et al. Altered monocyte cyclooxygenase response to lipopolysaccharide in type 1 diabetes. Diabetes. 2006;55(12):3439–45. doi:10.2337/db06-0447.
15. Tritt M, Sgouroudis E, d’Hennezel E, Albanese A, Piccirillo CA. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes. 2008;57(1):113–23. doi:10.2337/db06-1700.
16. Salvetti M, Ristori G, Bomprezzi R, Pozzilli P, Leslie RD. Twins: mirrors of the immune system. Immunol Today. 2000;21(7):342–7.
17. Carr EJ, Dooley J, Garcia-Perez JE, Lagou V, Lee JC, Wouters C, et al. The cellular composition of the human immune system is shaped by age and cohabitation. Nat Immunol. 2016. doi:10.1038/ni.3371.
18. Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012;379(9821):1142–54. doi:10.1016/S0140-6736(11)60276-6.
19. Schwartz SS, Epstein S, Corkey BE, Grant SF, Gavin JR, Aguilar RB. The time is right for a new classification system for diabetes: rationale and implications of the beta-cell-centric classification schema. Diabetes Care. 2016;39(2):179–86. doi:10.2337/dc15-1585. A recent review highlighting the fallibility of the current classification of diabetes and a call for a new approach.
20. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20(7):1183–97. doi:10.1007/s11892-016-0780-0
21. Leslie RD, Williams R, Pozzilli P. Clinical review: type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab. 2006;91(5):1654–9. doi:10.1210/jc.2005-1623.
22. Hawa MI, Buchan AP, Ola T, Wun CC, DeMicco DA, Bao W, et al. LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes. Diabetes Care. 2014;37(6):1643–9. doi:10.2337/dc13-2383. This study illustrates the potential of patients with autoimmune diabetes to remain without insulin therapy for many years.
23. Radtke MA, Midthjell K, Nilsen TI, Grill V. Heterogeneity of patients with latent autoimmune diabetes in adults: linkage to autoimmunity is apparent only in those with perceived need for insulin treatment: results from the Nord-Trondelag Health (HUNT) study. Diabetes Care. 2009;32(2):245–50. doi:10.2337/dc08-1468.
24. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes. 1999;48(1):150–7.
25. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group Lancet. 1997;350(9087):1288–93. One of the earliest and largest studies illustrating the high percentage of adult patients with diabetes who do not require insulin therapy, yet have diabetes autoantibodies.
26. Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care. 2007;30(4):932–8. doi:10.2337/dc06-1696.
27. Takeda H, Kawasaki E, Shimizu I, Konoue E, Fujiyama M, Murao S, et al. Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime Study). Diabetes Care. 2002;25(6):995–1001.
28. Maioli M, Pes GM, Delitala G, Puddu L, Falorni A, Tolu F, et al. Number of autoantibodies and HLA genotype, more than high titers of glutamic acid decarboxylase autoantibodies, predict insulin dependence in latent autoimmune diabetes of adults. Eur J Endocrinol/Eur Federation Endocrine Soc. 2010;163(4):541–9. doi:10.1530/eje-10-0427.
29. Zhou Z, Xiang Y, Ji L, Jia W, Ning G, Huang G, et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes. 2013;62(2):543–50. doi:10.2337/db12-0207. An important study in that it demonstrated that autoimmune diabetes, despite being strikingly different in children, is as frequent in adult Chinese as in North Europeans.
30. Zinman B, Kahn SE, Haffner SM, O’Neill MC, Heise MA, Freed MI, et al. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes. 2004;53(12):3193–200.
31. Maddaloni E, Lessan N, Al Tikriti A, Buzzetti R, Pozzilli P, Barakat MT. Latent autoimmune diabetes in adults in the United Arab Emirates: clinical features and factors related to insulin-requirement. PLoS One. 2015;10(8):e0131837. doi:10.1371/journal.pone.0131837.
32. Hawa MI, Kolb H, Schloot N, Beyan H, Paschou SA, Buzzetti R, et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: action LADA 7. Diabetes Care. 2013;36(4):908–13. doi:10.2337/dc12-0931. The largest study of diabetes autoantibodies in unselected adult-onset diabetes patients showing that most with autoimmune diabetes are not insulin dependent.
33. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38(3):320–3. doi:10.1038/ng1732.
34. Basile KJ, Guy VC, Schwartz S, Grant SF. Overlap of genetic susceptibility to type 1 diabetes, type 2 diabetes, and latent autoimmune diabetes in adults. Curr Diabetes Reports. 2014;14(11):550. doi:10.1007/s11892-014-0550-9.
35. Andersen MK, Sterner M, Forsen T, Karajamaki A, Rolandsson O, Forsblom C, et al. Type 2 diabetes susceptibility gene variants predispose to adult-onset autoimmune diabetes. Diabetologia. 2014;57(9):1859–68. doi:10.1007/s00125-014-3287-8.
36. Cervin C, Lyssenko V, Bakhtadze E, Lindholm E, Nilsson P, Tuomi T, et al. Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes. Diabetes. 2008;57(5):1433–7. doi:10.2337/db07-0299. One of the largest genetic studies suggesting that both major types of diabetes share genetic susceptibility.
37. Lukacs K, Hosszufalusi N, Dinya E, Bakacs M, Madacsy L, Panczel P. The type 2 diabetes-associated variant in TCF7L2 is associated with latent autoimmune diabetes in adult Europeans and the gene effect is modified by obesity: a meta-analysis and an individual study. Diabetologia. 2012;55(3):689–93. doi:10.1007/s00125-011-2378-z.
38. Horton V, Stratton I, Bottazzo GF, Shattock M, Mackay I, Zimmet P, et al. Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). UK Prospective Diabetes Study (UKPDS) Group. Diabetologia. 1999;42(5):608–16.
39. Vatay A, Rajczy K, Pozsonyi E, Hosszufalusi N, Prohaszka Z, Fust G, et al. Differences in the genetic background of latent autoimmune diabetes in adults (LADA) and type 1 diabetes mellitus. Immunol Lett. 2002;84(2):109–15. The largest study to date showing the genetic similarities between adult and childhood-onset autoimmune diabetes.
40. Caillat-Zucman S, Garchon HJ, Timsit J, Assan R, Boitard C, Djilali-Saiah I, et al. Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus. J Clin Invest. 1992;90(6):2242–50. doi:10.1172/JCI116110.
41. Desai M, Zeggini E, Horton VA, Owen KR, Hattersley AT, Levy JC, et al. An association analysis of the HLA gene region in latent autoimmune diabetes in adults. Diabetologia. 2007;50(1):68–73. doi:10.1007/s00125-006-0513-z.
42. Howson JM, Rosinger S, Smyth DJ, Boehm BO, Group A-ES, Todd JA. Genetic analysis of adult-onset autoimmune diabetes. Diabetes. 2011;60(10):2645–53. doi:10.2337/db11-0364.
43. Lampasona V, Petrone A, Tiberti C, Capizzi M, Spoletini M, di Pietro S, et al. Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: non insulin requiring autoimmune diabetes (NIRAD) 4. Diabetes Care. 2010;33(1):104–8. doi:10.2337/dc08-2305.
44. Davis TM, Wright AD, Mehta ZM, Cull CA, Stratton IM, Bottazzo GF, et al. Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia. 2005;48(4):695–702. doi:10.1007/s00125-005-1690-x.
45. Barker JM, Barriga KJ, Yu L, Miao D, Erlich HA, Norris JM, et al. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab. 2004;89(8):3896–902. doi:10.1210/jc.2003-031887.
46. Huang G, Yin M, Xiang Y, Li X, Shen W, Luo S, et al. Persistence of glutamic acid decarboxylase antibody (GADA) is associated with clinical characteristics of latent autoimmune diabetes in adults: a prospective study with 3-year follow-up. Diabetes Metab Res Rev. 2016. doi:10.1002/dmrr.2779.
47. Sorgjerd EP, Skorpen F, Kvaloy K, Midthjell K, Grill V. Time dynamics of autoantibodies are coupled to phenotypes and add to the heterogeneity of autoimmune diabetes in adults: the HUNT study. Norway Diabetologia. 2012;55(5):1310–8. doi:10.1007/s00125-012-2463-y.
48. Hagopian WA, Karlsen AE, Gottsater A, Landin-Olsson M, Grubin CE, Sundkvist G, et al. Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type. J Clin Invest. 1993;91(1):368–74. doi:10.1172/JCI116195.
49. Signore A, Capriotti G, Chianelli M, Bonanno E, Galli F, Catalano C, et al. Detection of insulitis by pancreatic scintigraphy with 99mTc-labeled IL-2 and MRI in patients with LADA (Action LADA 10). Diabetes Care. 2015;38(4):652–8. doi:10.2337/dc14-0580.
50. Brooks Worrell B, Warsen A, Palmer JP. Improved T cell assay for identification of type 1 diabetes patients. J Immunol Methods. 2009;344(1):79–83. doi:10.1016/j.jim.2009.03.004.
51. Brooks-Worrell BM, Juneja R, Minokadeh A, Greenbaum CJ, Palmer JP. Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients. Diabetes. 1999;48(5):983–8.
52. Brooks-Worrell BM, Starkebaum GA, Greenbaum C, Palmer JP. Peripheral blood mononuclear cells of insulin-dependent diabetic patients respond to multiple islet cell proteins. J Immunol. 1996;157(12):5668–74.
53. Brooks-Worrell BM, Reichow JL, Goel A, Ismail H, Palmer JP. Identification of autoantibody-negative autoimmune type 2 diabetic patients. Diabetes Care. 2011;34(1):168–73. doi:10.2337/dc10-0579. A provocative study suggesting that a proportion of adult non-insulin requiring diabetes patients have autoimmune T cell responses yet are without autoantibodies.
54. Deng C, Xiang Y, Tan T, Ren Z, Cao C, Huang G et al. Altered peripheral B-lymphoctye subsets in type 1 diabetes and latent autoimmune diabetes in adults. Diabetes Care. 2015. doi:10.2337/dc15-1765
55. Leete P, Willcox A, Krogvold L, Dahl-Jorgensen K, Foulis AK, Richardson SJ, et al. Differential insulitic profiles determine the extent of beta cell destruction and the age at onset of type 1 diabetes. Diabetes. 2016. doi:10.2337/db15-1615.
56. Arif S, Leete P, Nguyen V, Marks K, Nor NM, Estorninho M, et al. Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes. 2014;63(11):3835–45. doi:10.2337/db14-0365. An important study, one of several, illustrating differences in the immune characteristics of patients with type 1 diabetes according to their age at onset.
57. Juneja R, Hirsch IB, Naik RG, Brooks-Worrell BM, Greenbaum CJ, Palmer JP. Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes. Metabolism. 2001;50(9):1008–13.
58. Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia. 2005;48(11):2206–12. doi:10.1007/s00125-005-1960-7.
59. Pipeleers D, Ling Z. Pancreatic beta cells in insulin-dependent diabetes. Diabetes Metab Rev. 1992;8(3):209–27.
60. Keskinen P, Korhonen S, Kupila A, Veijola R, Erkkilä S, Savolainen H, et al. First-phase insulin response in young healthy children at genetic and immunological risk for type I diabetes. Diabetologia. 2002;45(12):1639–48.
61. Kibirige M, Metcalf B, Renuka R, Wilkin TJ. Testing the accelerator hypothesis: The relationship between body mass and age at diagnosis of type 1 diabetes. Diabetes Care. 2003;26(10):2865–70.
62. Bingley PJ, Bonifacio E, Gale EAM. Can we really predict IDDM? Diabetes. 1993;42(2):213–20.
63. Gorus FK. Diabetes registries and early biological markers of insulin-dependent diabetes mellitus. Diabetes Metab Rev. 1997;13(4):247–74.
64. Hawa MI, Thivolet C, Mauricio D, Alemanno I, Cipponeri E, Collier D, et al. Metabolic syndrome and autoimmune diabetes: action LADA 3. Diabetes Care. 2009;32(1):160–4. doi:10.2337/dc08-1419.
65. Carlsson A, Sundkvist G, Groop L, Tuomi T. Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab. 2000;85(1):76–80. doi:10.1210/jcem.85.1.6228.
66. Juhl CB, Bradley U, Holst JJ, Leslie RD, Yderstraede KB, Hunter S. Similar weight-adjusted insulin secretion and insulin sensitivity in short-duration late autoimmune diabetes of adulthood (LADA) and type 2 diabetes: action LADA 8. Diabetic Med J British Diabetic Assoc. 2014;31(8):941–5. doi:10.1111/dme.12434.
67. Johansen OE, Boehm BO, Grill V, Torjesen PA, Bhattacharya S, Patel S, et al. C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study. Diabetes Care. 2014;37(1):e11–2. doi:10.2337/dc13-1523.
68. Buzzetti R, Pozzilli P, Frederich R, Iqbal N, Hirshberg B. Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). Diabetes Metab Res Rev. 2015. doi:10.1002/dmrr.2717.
69. Zhao Y, Yang L, Xiang Y, Liu L, Huang G, Long Z, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains beta-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. J Clin Endocrinol Metab. 2014;99(5):E876–80. doi:10.1210/jc.2013-3633.
70. Brophy S, Davies H, Mannan S, Brunt H, Williams R. Interventions for latent autoimmune diabetes (LADA) in adults. The Cochrane database of systematic reviews. 2011(9):Cd006165. doi:10.1002/14651858.CD006165.pub3.
71. Andersen CD, Bennet L, Nystrom L, Lindblad U, Lindholm E, Groop L, et al. Worse glycaemic control in LADA patients than in those with type 2 diabetes, despite a longer time on insulin therapy. Diabetologia. 2013;56(2):252–8. doi:10.1007/s00125-012-2759-y.
72. Zampetti S, Capizzi M, Spoletini M, Campagna G, Leto G, Cipolloni L, et al. GADA titer-related risk for organ-specific autoimmunity in LADA subjects subdivided according to gender (NIRAD study 6). J Clin Endocrinol Metab. 2012;97(10):3759–65. doi:10.1210/jc.2012-2037.
73. Isomaa B, Almgren P, Henricsson M, Taskinen MR, Tuomi T, Groop L, et al. Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). Diabetes Care. 1999;22(8):1347–53.
74. Myhill P, Davis WA, Bruce DG, Mackay IR, Zimmet P, Davis TM. Chronic complications and mortality in community-based patients with latent autoimmune diabetes in adults: the Fremantle Diabetes Study. Diabetic Med J British Diabetic Assoc. 2008;25(10):1245–50. doi:10.1111/j.1464-5491.2008.02562.x.
75. Roh MO, Jung CH, Kim BY, Mok JO, Kim CH. The prevalence and characteristics of latent autoimmune diabetes in adults (LADA) and its relation with chronic complications in a clinical department of a university hospital in Korea. Acta Diabetol. 2013;50(2):129–34. doi:10.1007/s00592-010-0228-y.
76. Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, et al. B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabetes Care. 2014;37(2):453–9. doi:10.2337/dc13-0626.